Kwon H, et al. • Spontaneously Reported Hepatic Adverse Drug Events Clinical characteristics of acute toxic liver injury. Korean J Hepatol 2004; 10: 125-34. 7. Seo JC, Jeon WJ, Park SS, Kim SH, Lee KM, Chae HB, Park SM, Youn SJ. Clinical expeience of 48 acute toxic hepatitis patients. Korean J Hepatol 2006; 12: 74-81. 8. Wai CT, Tan BH, Chan CL, Sutedja DS, Lee YM, Khor C, Lim SG. Drug- induced liver injury at an Asian center: a prospective study. Liver Int 2007; 27: 465-74. 9. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García- Ruiz E, García-Muñoz B, González-Grande R, Pizarro A, Durán JA, Jiménez M, Rodrigo L, Romero-Gomez M, Navaro JM, Planas R, Costa J, Borras A, Soler A, Salmerón J, Martin-Vivaldi R; Spanish Group for the Study of Drug-induced Liver Disease. Drug-induced liver injury: an anal- ysis of 461 incidences submitted to the Spanish registry over a 10-year pe- riod. Gastroenterology 2005; 129: 512-21. 10. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Daven T, Serano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34. 11. Shin YS, Lee YW, Choi YH, Park BJ, Jee YK, Choi SK, Kim EG, Park JW, Hong CS. Spontaneous reporting of adverse drug events by Korean region- al pharmacovigilance centers. Pharmacoepidemiol Drug Saf 2009; 18: 910-5. 12. Moride Y, Haramburu F, Requejo AA, Bégaud B. Under-reporting of ad- verse drug reactions in general practice. Br J Clin Pharmacol 1997; 43: 177-81. 13. Vallano A, Cereza G, PedróS C, Agusti A, Danés I, Aguilera C, Arnau JM. Obstacles and solutions for spontaneous reporting of adverse drug reac- tions in the hospital. Br J Clin Pharmacol 2005; 60: 653-8. 14. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disporportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmaco- epidemiol Drug Saf 2002; 11: 3-10. 15. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advan- tages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 2004; 13: 519-23. 16. The Uppsala Monitoring Centre. The WHO-ART Adverse Reaction Ter- minology. Uppsala: the Uppsala Monitoring Centre, 2005. 17. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-9. 18. Shin YS, Park JW, Lee YW, Kim CW, Dhong HJ, Park HS, Cho YJ, Cho SH, Pyun BY, Lee KH, Lee HR, Hong CS. Current status of oriental med- icine in treating Korean allergy patients. Pharmacoepidemiol Drug Saf 2011; 20: 99-104. 19. WHO and the Uppsala Monitoring Centre. Safety monitoring of medici- nal products: Guidelines for setting up and running a pharmacovigi- lance centre. Uppsala: the Uppsala Monitoring Centre, 2000. 20. Song JH, Joo EJ. The crisis of antimicrobial resistance: current status and future strategies. J Korean Med Assoc 2010; 53: 999-1005. 21. Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil O, Hay JE, Hynan L, Crippin JS, Blei AT, Samu- el G, Reisch J, Lee WM; U.S. Acute Liver Failure Study Group. Results of prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-54. 22. Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reac- tion reporting in one English health region. BMJ 1999; 319: 1541. 23. Agarwal VK, McHutchison JG, Hoofnagle JH; Drug-induced Liver Inju- ry Network. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010; 8: 463-70. 24. Danan G, Benichou C. Causality assessment of adverse reactions to drugs: I. A novel method based on the conclusions of international con- sensus meetings: application to drug-induced liver injuries. J Clin Epide- miol 1993; 46: 1323-30. 25. Benichou C, Danan G, Flahault A. Causality assessment of adverse reac- tions to drugs: II. An original model for validation of drug causality assess- ment methods: Case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-6. 26. Rochon J, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S, Watkins PB, Davern T, McHutchison JG; Drug-induced liver injury network (DILIN). Reliability of Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 2008; 48: 1175-83. 27. Akhtar AJ, Shaheen M. Jaundice in African-American and Hispanic pa- tients with AIDS. J Natl Med Assoc 2007; 99: 1381-5. 28. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchenik AE. Anti-tuberculosis drug-inuced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157: 1871-6. 29. Shapiro MA, Lewis JH. Causality assessment of drug-induced hepato- toxicity: promises and pitfalls. Clin Liver Dis 2007; 11: 477-505. http://dx.doi.org/10.3346/jkms.2012.27.3.268 http://jkms.org 273